Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
1 093,811 096,521 100,221 091,51
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
608,77608,77612,97608,77
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
1 254,811 253,011 253,871 226,33
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
1 761,111 764,271 766,881 744,71
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
642,58644,87648,48640,18
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
851,13855,66858,75845,56
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
217,98217,98218,65216,88
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
3 211,833 227,213 268,383 226,55
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
948,98948,58957,83941,97
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
1 474,521 479,031 481,041 466,80
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
2 392,122 396,952 421,222 382,32
ATAI:NASDAQ
AtaiBeckley Inc
4,14 US$
-0,60%
(-0,025) 1D
4,11 US$
-0,58% (-0,024)
After hours
Closed: 1 მაი, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATAI...
Open
4,15 US$
High
4,20 US$
Low
4,08 US$
Mkt. cap
1,52 მლრდ.
Avg. vol.
6,58 მლნ.
Volume
2,36 მლნ.
52-wk high
6,72 US$
52-wk low
1,29 US$
EPS
-2,91 US$
Beta
1,57
Shares outstanding
366,92 მლნ.
No. of employees
99
News stories
From sources across the web
Profile
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
About AtaiBeckley Inc
CEOფლორიან ბრანდ
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
მარ. 2025
ივნ. 2025
სექ. 2025
დეკ. 2025
Revenue
1,56 მლნ.
719,00 ათ.
749,00 ათ.
1,07 მლნ.
Cost of goods sold
10,84 მლნ.
10,51 მლნ.
14,68 მლნ.
10,91 მლნ.
Cost of revenue
10,84 მლნ.
10,51 მლნ.
14,68 მლნ.
10,91 მლნ.
Research and development expenses
-
582,00 ათ.
-
4,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,99 მლნ.
14,90 მლნ.
14,50 მლნ.
24,40 მლნ.
Operating expense
9,99 მლნ.
15,48 მლნ.
14,50 მლნ.
28,41 მლნ.
Total operating expenses
20,82 მლნ.
25,99 მლნ.
29,18 მლნ.
39,32 მლნ.
Operating income
-19,27 მლნ.
-25,27 მლნ.
-28,44 მლნ.
-38,25 მლნ.
Other non operating income
-13,01 მლნ.
-6,33 მლნ.
-51,25 მლნ.
13,99 მლნ.
EBT including unusual items
-26,34 მლნ.
-27,68 მლნ.
-61,00 მლნ.
-544,84 მლნ.
EBT excluding unusual items
-32,54 მლნ.
-30,16 მლნ.
-79,20 მლნ.
-23,71 მლნ.
Income tax expense
128,00 ათ.
65,00 ათ.
102,00 ათ.
3,00 ათ.
Effective tax rate
-0,49%
-0,23%
-0,17%
-
Other operating expenses
-
-
-
-
Net income
-26,43 მლნ.
-27,73 მლნ.
-61,07 მლნ.
-544,81 მლნ.
Net profit margin
-1 699,74%
-3 856,61%
-8 154,07%
-51 108,16%
Earnings per share
-0,15
-0,14
-0,28
-1,73
Interest and investment income
186,00 ათ.
248,00 ათ.
504,00 ათ.
542,00 ათ.
Interest expense
-900,00 ათ.
-264,00 ათ.
-
-
Net interest expenses
-714,00 ათ.
-16,00 ათ.
504,00 ათ.
542,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,05 მლნ.
-25,05 მლნ.
-28,20 მლნ.
-37,91 მლნ.
Gain or loss from assets sale
-
-
-
692,00 ათ.
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more